Table 1.
Baseline characteristics of patients
| Characteristics | Nivolumab (N = 256) |
|---|---|
| Sex, n (%) | |
| Male | 202 (78.9) |
| Female | 54 (21.1) |
| Age, years | |
| Median (range) | 66 (20–84) |
| Age ≥ 75 years, n (%) | 24 (9.4) |
| Primary cancer site, n (%) | |
| Hypopharynx | 64 (25.0) |
| Oral cavity | 56 (21.9) |
| Oropharynx | 40 (15.6) |
| Salivary glands* | 23 (9.0) |
| Larynx | 21 (8.2) |
| Nasopharynx* | 19 (7.4) |
| Maxillary sinus* | 14 (5.5) |
| Others* | 19 (7.4) |
| Presence of another primary malignancy, n (%) | |
| Yes* | 49 (19.1) |
| No | 199 (77.7) |
| Unknown | 8 (3.1) |
| Head and neck cancer histology, n (%) | |
| Squamous cell carcinoma | 217 (84.8) |
| Non-Squamous cell carcinoma* | 29 (11.3) |
| Not Evaluated* | 9 (3.5) |
| ECOG PS, n (%) | |
| 0 | 118 (46.1) |
| 1 | 97 (37.9) |
| 2* | 23 (9.0) |
| 3* | 6 (2.3) |
| 4* | 2 (0.8) |
| Unknown* | 10 (3.9) |
| Cancer stage at nivolumab initiation, n (%) | |
| I* | 11 (4.3) |
| II* | 30 (11.7) |
| III | 22 (8.6) |
| IVA | 114 (44.5) |
| IVB | 29 (11.3) |
| IVC | 33 (12.9) |
| Unknown* | 17 (6.6) |
| Nivolumab treatment line for recurrent or metastatic head and neck cancer, n (%)** | |
| 1st | 70 (27.3) |
| 2nd | 110 (43.0) |
| 3rd | 45 (17.6) |
| 4th or later | 31 (12.1) |
ECOG Eastern Cooperative Oncology Group
*Patients with these characteristics were excluded from the CheckMate 141 study [1]
**Nivolumab treatment line was counted as the number of systemic chemotherapy for recurrent or metastatic HNC